FCM
FLGT icon

Fortis Capital Management’s Fulgent Genetics FLGT Stock Holding History

Fortis Capital Management’s Portfolio FLGT Stock Details FLGT Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2021
Q3 		– Sell
-5,800
Closed -$535K – 116
2021
Q2 		$535K Buy
+5,800
New +$463K 0.27% 100

Other funds holding FLGT

BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return
JP Morgan Chase
JP Morgan Chase New York $1.56T AUM 27.86% 1-Year Est. Return
BBA
Baker Bros. Advisors New York $17.4B AUM 131.5% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return
Invesco
Invesco Atlanta, Georgia $1.02T AUM 30.18% 1-Year Est. Return
Northern Trust
Northern Trust Chicago, Illinois $757B AUM 28.64% 1-Year Est. Return
Citadel Advisors
Citadel Advisors Miami, Florida $618B AUM 30.34% 1-Year Est. Return
Point72 Asset Management
Point72 Asset Management Stamford, Connecticut $78.1B AUM 55.25% 1-Year Est. Return

Fortis Capital Management's FLGT Position: Q3 2021 in Review

Fortis Capital Management sold out of Fulgent Genetics (FLGT) in Q3 2021, closing a stake of 5,800 shares — an estimated $535K sold.

Fortis Capital Management first reported a position in FLGT in Q2 2021 and held it in 1 quarter. The position peaked at $535K in Q2 2021. 268 funds tracked by Wall St. Rank hold FLGT as of Q3 2021.

  • Fortis Capital Management reported no remaining Fulgent Genetics position as of Q3 2021 after selling out during the quarter.
  • Fortis Capital Management sold 5,800 Fulgent Genetics shares in Q3 2021, an estimated $535K.
  • Fortis Capital Management first reported a position in Fulgent Genetics in Q2 2021 and held it in 1 quarter.
  • Fortis Capital Management's Fulgent Genetics position peaked at $535K in Q2 2021.
  • 268 funds tracked by Wall St. Rank held Fulgent Genetics as of Q3 2021.

Based on Fortis Capital Management's 13F filing for Q3 2021, filed 15 Nov 2021.